Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer

Award Number: R01CA318433
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/06/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer - PROJECT SUMMARY Prostate cancer is the most prevalent cancer among US veterans, and the Veterans Affairs Health System (VA) cares for 15,000 new cases each year. Castration-resistant prostate cancer (CRPC) is difficult to treat, typically requiring toxic chemotherapies which achieve only modest benefit. Unfortunately, progress has been slow, and there has been a drought of new treatments for CRPC. Radioligand therapy (therapeutic radioactive isotopes targeted to malignant cells) is a new, effective class of treatments for CRPC. In 2022 Lutetium Lu-177 vipivotide tetraxetan (Lu-177) became the first FDA-approved radioligand for CRPC after demonstrating improved overall survival and reduced toxicity in clinical trials. Due to these promising results, Lu-177’s approval was met with great excitement from both providers and patients. However, access to Lu-177 therapy within the Veterans Affairs Health System (VA) is unknown. The high infrastructure requirements necessary to administer Lu-177 may cause access barriers; the VA has far fewer sites capable of administering Lu-177 compared to non-VA providers. The VA Community Care program (VACC) – in which the VA pays for veterans to receive care from non-VA providers – may help mitigate access barriers, but the VACC has faced prolonged wait times and quality-of-care concerns. In addition, the clinical outcomes of Lu-177 within the veteran population have not been evaluated; clinical trial results often fail to generalize to real-world patient populations that are typically older and more comorbid than those enrolled on trials, resulting in diminished survival benefit and increased toxicity. To address these knowledge gaps, we propose to describe access to and outcomes of Lu-177 therapy among US veterans. We will apply national, Medicare-linked VA data to identify veterans diagnosed with prostate cancer and measure care delivered by both VA and non-VA providers to achieve a comprehensive understanding of veteran access and outcomes. Aim 1: Measure adoption and access to Lu-177 therapy for US veterans. Using national VA data linked to Medicare claims, we will compare Lu-177 adoption within the VA to non-veteran patients treated in community settings (Flatiron Health) (Aim 1A), and assess geographic and income-based access barriers within the VA (Aim 1B). Aim 2: Measure clinical outcomes of Lu-177 therapy among US veterans. We will measure overall survival (Aim 2A) and treatment toxicity (Aim 2B) among veterans treated with Lu-177, compared to clinical trial participants and to non-veteran patients treated in community settings. Aim 3: Evaluate the role of VA Community Care in providing access to Lu-177 therapy. We will measure access to (Aim 3A) and outcomes of (Aim 3B) Lu-177 therapy for veterans receiving treatment within VA facilities vs. via VACC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $708,377 )
2026	2026	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Cause and Prevention Research	000	1	8/6/2026	NEW	$708,377
														Subtotal = $708,377

Grand Total All Awards = $708,377

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer

Award Number: R01CA318433

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/06/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer